species-dependent metabolism of efavirenz produces a nephrotoxic glutathione
conjugate in rats. Toxicol Appl Pharmacol 2000;169:102–113.
Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil
considerably increases the plasma concentrations of rosiglitazone. Diabetologia
2003a;46:1319–1323.
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil,
itraconazole, and their combination on the pharmacokinetics and pharmacody-
namics of repaglinide: potentially hazardous interaction between gemfibrozil and
repaglinide. Diabetologia 2003b;46:347–351.
Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P,
Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-
dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug
Metab Dispos 2006;34:191–197.
Parker RJ, Hirom PC, Millburn P. Enterohepatic recycling of phenolphthalein,
morphine, lysergic acid diethylamide (LSD) and diphenylacetic acid in the rat.
Hydrolysis of glucuronic acid conjugates in the gut lumen. Xenobiotica 1980;10:689–
703.
Parkinson A. Biotransformation of xenobiotics. In: Klassen CD, editor. Casarett &
Doull’s Toxicology: The Basic Science of Poisons McGraw-Hill; 2001. p 133–224.
Product Note for guidance on the investigation of drug interactions (CPMP/EWP/560/
95). Available atwww.eudra.org/humandocs/humans/EWP.html.
Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge
the gap between cDNA-expressed cytochromes P450 and native human liver
microsomes. Biochem Pharmacol 1999;57:465–480.
Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the
organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated
hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the
mechanism of the clinically relevant drug–drug interaction between cerivastatin and
gemfibrozil. J Pharmacol Exp Ther 2004;311:228–236.
Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, Rodrigues AD. Evaluation
of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and
correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7:
375–388.
Solon EG, Balani SK, Lee FW. Whole-body autoradiography in drug discovery. Curr
Drug Metab 2002;3:451–462.
Solon EG, Kraus L. Quantitative whole-body autoradiography in the pharmaceutical
industry. Survey results on study design, methods, and regulatory compliance. J
Pharmacol Toxicol Methods 2001;46:73–81.
Sumner SCJ, Stedman DB, Clarke DO, Welsch F, Fennell TR. Characterization of
urinary metabolites from [1,2,methoxy-^13 C]-2-methoxyethanol in mice using^13 C
nuclear magnetic resonance spectroscopy. Chem Res Toxicol 1992;5:553–560.
US Food and Drug Administration Guidance for industry: drug metabolism/drug
interaction studies in the drug development process: studiesin vitro. Available at
http://www.fda.gov/cder/guidance.html.
Valentin J. Basic anatomical and physiological data for use in radiological protection:
reference values: ICRP Publication 89. Annals of the ICRP 2002;32:1–277.
284 ROLE OF DRUG METABOLISM IN DRUG DEVELOPMENT